Skip to main content
. 2020 Mar 27;182(6):583–594. doi: 10.1530/EJE-19-0762

Table 8.

Number of patients with last available HbA1c <7%* at study end, according to baseline diabetic status. Data based on 173 patients who received at least one dose of pasireotide during the extension phase. See Methods section for definitions of diabetic status.

Baseline diabetic status Long-acting pasireotide 40 mg Long-acting pasireotide 60 mg Crossover group
Diabetic, n
 HbA1c, n (%)		 38
21 (55.3)		 32
10 (31.3)		 44
22 (50.0)
Pre-diabetic, n
 HbA1c, n (%)		 12
11 (91.7)		 12
9 (75.0)		 17
16 (94.1)
NGT, n
 HbA1c, n (%)		 7
6 (85.7)		 10
9 (90.0)		 1
1 (100.0)

NGT, normal glucose tolerance.

*Target HbA1c level set by the American Diabetes Association and European Association for the Study of Diabetes (11, 12).